09:03 AM EST, 01/29/2025 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Wednesday that the non-profit organization Hema-Quebec will begin reimbursing HyQvia for patients with primary or secondary humoral immunodeficiencies aged two and older starting Jan. 30 in Quebec, Canada.

The company said HyQvia, a subcutaneous immune globulin infusion indicated for immune system deficiencies that increase infection risk, received Health Canada approval for adults in 2022 and pediatric patients in 2024.